Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy

Primary signet-ring cell carcinoma of the urinary bladder is extremely rare and patient survival is very poor. The disease usually presents at advanced stages because the cancer progresses rapidly. The only option for effective treatment is radical cystectomy, and no effective chemotherapy has been...

Full description

Saved in:
Bibliographic Details
Main Authors: Takashi Hamakawa, Yoshiyuki Kojima, Taku Naiki, Yasue Kubota, Takahiro Yasui, Keiichi Tozawa, Yutaro Hayashi, Kenjiro Kohri
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Case Reports in Urology
Online Access:http://dx.doi.org/10.1155/2013/915874
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850223224666718208
author Takashi Hamakawa
Yoshiyuki Kojima
Taku Naiki
Yasue Kubota
Takahiro Yasui
Keiichi Tozawa
Yutaro Hayashi
Kenjiro Kohri
author_facet Takashi Hamakawa
Yoshiyuki Kojima
Taku Naiki
Yasue Kubota
Takahiro Yasui
Keiichi Tozawa
Yutaro Hayashi
Kenjiro Kohri
author_sort Takashi Hamakawa
collection DOAJ
description Primary signet-ring cell carcinoma of the urinary bladder is extremely rare and patient survival is very poor. The disease usually presents at advanced stages because the cancer progresses rapidly. The only option for effective treatment is radical cystectomy, and no effective chemotherapy has been established for this variant. We report a case of signet-ring cell carcinoma of the urinary bladder with a long-term survival of 90 months owing to radical cystectomy and combination adjuvant chemotherapy with S-1 and cisplatin. To our knowledge, this is the first report to demonstrate the long-term therapeutic activity of combination S-1 and cisplatin adjuvant chemotherapy against invasive signet-ring cell carcinoma of the urinary bladder.
format Article
id doaj-art-5e0f8d0632c24e2a880df1cee8a0907c
institution OA Journals
issn 2090-696X
2090-6978
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Case Reports in Urology
spelling doaj-art-5e0f8d0632c24e2a880df1cee8a0907c2025-08-20T02:06:03ZengWileyCase Reports in Urology2090-696X2090-69782013-01-01201310.1155/2013/915874915874Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant ChemotherapyTakashi Hamakawa0Yoshiyuki Kojima1Taku Naiki2Yasue Kubota3Takahiro Yasui4Keiichi Tozawa5Yutaro Hayashi6Kenjiro Kohri7Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, JapanPrimary signet-ring cell carcinoma of the urinary bladder is extremely rare and patient survival is very poor. The disease usually presents at advanced stages because the cancer progresses rapidly. The only option for effective treatment is radical cystectomy, and no effective chemotherapy has been established for this variant. We report a case of signet-ring cell carcinoma of the urinary bladder with a long-term survival of 90 months owing to radical cystectomy and combination adjuvant chemotherapy with S-1 and cisplatin. To our knowledge, this is the first report to demonstrate the long-term therapeutic activity of combination S-1 and cisplatin adjuvant chemotherapy against invasive signet-ring cell carcinoma of the urinary bladder.http://dx.doi.org/10.1155/2013/915874
spellingShingle Takashi Hamakawa
Yoshiyuki Kojima
Taku Naiki
Yasue Kubota
Takahiro Yasui
Keiichi Tozawa
Yutaro Hayashi
Kenjiro Kohri
Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy
Case Reports in Urology
title Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy
title_full Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy
title_fullStr Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy
title_full_unstemmed Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy
title_short Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy
title_sort long term survival of a patient with invasive signet ring cell carcinoma of the urinary bladder managed by combined s 1 and cisplatin adjuvant chemotherapy
url http://dx.doi.org/10.1155/2013/915874
work_keys_str_mv AT takashihamakawa longtermsurvivalofapatientwithinvasivesignetringcellcarcinomaoftheurinarybladdermanagedbycombineds1andcisplatinadjuvantchemotherapy
AT yoshiyukikojima longtermsurvivalofapatientwithinvasivesignetringcellcarcinomaoftheurinarybladdermanagedbycombineds1andcisplatinadjuvantchemotherapy
AT takunaiki longtermsurvivalofapatientwithinvasivesignetringcellcarcinomaoftheurinarybladdermanagedbycombineds1andcisplatinadjuvantchemotherapy
AT yasuekubota longtermsurvivalofapatientwithinvasivesignetringcellcarcinomaoftheurinarybladdermanagedbycombineds1andcisplatinadjuvantchemotherapy
AT takahiroyasui longtermsurvivalofapatientwithinvasivesignetringcellcarcinomaoftheurinarybladdermanagedbycombineds1andcisplatinadjuvantchemotherapy
AT keiichitozawa longtermsurvivalofapatientwithinvasivesignetringcellcarcinomaoftheurinarybladdermanagedbycombineds1andcisplatinadjuvantchemotherapy
AT yutarohayashi longtermsurvivalofapatientwithinvasivesignetringcellcarcinomaoftheurinarybladdermanagedbycombineds1andcisplatinadjuvantchemotherapy
AT kenjirokohri longtermsurvivalofapatientwithinvasivesignetringcellcarcinomaoftheurinarybladdermanagedbycombineds1andcisplatinadjuvantchemotherapy